NeonMind Appoints Canadian Medical Leader In Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC To Its Specialty Clinics Advisory Board
January 13, 2022
Ryan Allway January 13th, 2022 Psychedelics Dr. Bainbridge’s Expertise and Network Provides Safety Best-Practices for Administration of Intravenous Ketamine (IV-Ketamine) at NeonMind Clinics Vancouver, B.C. – January 13, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company, announced... Read more
Revitalist Increases Clinic Count to Nine With Closing of Florida Clinic Acquisition
January 12, 2022
Ryan Allway January 12th, 2022 Psychedelics, Top News REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce that it has executed an asset purchase agreement (“Agreement”) dated January 11, 2022, to acquire a Ketamine clinic located in Jacksonville, Florida... Read more
Ryan Allway January 11th, 2022 Psychedelics Company poised for rapid expansion in 2022 after highly successful 2021, in which it secured commercial deployments across three continents, US FDA registration and multiple awards for innovation in AI VANCOUVER, BC, Jan. 11, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE:... Read more
Ryan Allway January 11th, 2022 Psychedelics TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), announced that it has begun to examine the possibility of including psychedelic... Read more
Ryan Allway January 10th, 2022 Psychedelics Research will focus on developing novel patentable psychedelics as potential drug candidates TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel... Read more
Tripsitter Clinic Ltd. Announces Dual Listing on Frankfurt Stock Exchange, Marketing Agreement and Appointment of Richard Dolan as Director
January 10, 2022
Ryan Allway January 10th, 2022 Psychedelics TORONTO, Jan. 10, 2022 /PRNewswire/ – Tripsitter Clinic Ltd. (CSE: KETA) (FSE: UY0) (“TripSitter Clinic” or the “Company“), a virtual clinic and tele-health company, is pleased to announce that the Company’s shares have been accepted for listing on the Frankfurt Stock Exchange (“FSE”) and commenced... Read more
Revitalist to Participate in the H.C. Wainwright Bioconnect Conference in January 2022
January 7, 2022
Ryan Allway January 7th, 2022 Psychedelics, Top News REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) is pleased to announce that President & Chief Executive Officer, Kathryn Walker, will present virtually at the H.C. Wainwright Bioconnect Conference taking place on January 10-13,... Read more
3 Ways to Invest in Ketamine Clinics
January 6, 2022
Ryan Allway January 6th, 2022 App, Exclusive, Psychedelics, Top Story Researchers believe that psychedelics may revolutionize mental health treatments, but FDA-approved psychedelics remain out of reach—with one exception. Unlike psilocybin or MDMA, ketamine is FDA-approved for anesthesia during medical procedures, opening the door to off-label use as a treatment... Read more
Silo Wellness Appoints CEO Douglas K. Gordon to Board of Directors and Provides Corporation Updates
Oregon January 6, 2022
Ryan Allway January 6th, 2022 Psychedelics Toronto, Ontario–(Newsfile Corp. – January 6, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, is pleased to announce that the Company’s Chief Executive Officer, Douglas K. Gordon, has been appointed... Read more
Filament Health Announces Health Canada Approval For Phase II Trial Administering New Psilocybin Microdose Formulation
January 4, 2022
Ryan Allway January 4th, 2022 Psychedelics The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjectswith persistent depressive disorder VANCOUVER, BC, Jan. 4, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced... Read more
